SHARP1 suppresses angiogenesis of endometrial cancer by decreasing hypoxia-inducible factor-1α level

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Liao, Yun ^a   Lu, Wen ^b   Che, Qi ^b   Yang, Tingting ^b   Qiu, Haifeng ^b   Zhang, Huijuan ^a   He, Xiaoying ^a   Wang, Jingyun ^a   Qiu, Meiting ^a   Zou, Yingfen ^a   Gu, Wei ^a   Wan, Xiaoping ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE 4; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; SHARP1 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; BHLHE41 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ANGPTL4 GENE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CA9 GENE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CELL VIABILITY; CONTROLLED STUDY; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SHARP1 GENE; TUMOR INVASION; TUMOR VASCULARIZATION; VEGFA GENE; AGED; CAPILLARY PERMEABILITY; CASE CONTROL STUDY; CELL SURVIVAL; DISEASE COURSE; ENDOMETRIUM TUMOR; GENETICS; MICROVASCULATURE; MIDDLE AGED; MYOMETRIUM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; UPREGULATION;

ADULT; AGED; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CAPILLARY PERMEABILITY; CASE-CONTROL STUDIES; CELL SURVIVAL; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICROVESSELS; MIDDLE AGED; MYOMETRIUM; NEOVASCULARIZATION, PATHOLOGIC; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903390323     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099907     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Di Cristofano A, Ellenson LH (2007) Endometrial carcinoma. Annu Rev Pathol 2: 57-85. (Pubitemid 46448060)
3. Hill EK, Dizon DS (2012) Medical therapy of endometrial cancer: current status and promising novel treatments. Drugs 72: 705-713.
4. Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, et al. (2011) Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 29: 3278-3285.
5. Vale CL, Tierney J, Bull SJ, Symonds PR (2012) Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 8: CD003915.
6. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
7. Risau W (1997) Mechanisms of angiogenesis. Nature 386: 671-674.
8. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364. (Pubitemid 26272076)
9. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18.
10. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410. (Pubitemid 37328844)
11. Baeriswyl V, Christofori G (2009) The angiogenic switch in carcinogenesis. Semin Cancer Biol 19: 329-337.
12. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027. (Pubitemid 46202320)
13. Ostergaard L, Tietze A, Nielsen T, Drasbek KR, Mouridsen K, et al. (2013) The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis. Cancer Res 73: 5618-5624.
14. Kafousi M, Vrekoussis T, Tsentelierou E, Pavlakis K, Navrozoglou I, et al. (2012) Immunohistochemical study of the angiogenetic network of VEGF, HIF1alpha, VEGFR-2 and endothelial nitric oxide synthase (eNOS) in human breast cancer. Pathol Oncol Res 18: 33-41.
15. Ozbudak IH, Karaveli S, Simsek T, Erdogan G, Pestereli E (2008) Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. Gynecol Oncol 108: 603-608.
16. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358: 2039-2049.
17. Fujimoto K, Shen M, Noshiro M, Matsubara K, Shingu S, et al. (2001) Molecular cloning and characterization of DEC2, a new member of basic helix-loop-helix proteins. Biochem Biophys Res Commun 280: 164-171. (Pubitemid 32917491)
18. Fujimoto K, Hamaguchi H, Hashiba T, Nakamura T, Kawamoto T, et al. (2007) Transcriptional repression by the basic helix-loop-helix protein Dec2: multiple mechanisms through E-box elements. Int J Mol Med 19: 925-932.
19. Azmi S, Taneja R (2002) Embryonic expression of mSharp-1/mDEC2, which encodes a basic helix-loop-helix transcription factor. Mech Dev 114: 181-185. (Pubitemid 34462971)
20. Azmi S, Sun H, Ozog A, Taneja R (2003) mSharp-1/DEC2, a basic helix-loop-helix protein functions as a transcriptional repressor of E box activity and Stra13 expression. J Biol Chem 278: 20098-20109. (Pubitemid 36799204)
21. Liu Y, Sato F, Kawamoto T, Fujimoto K, Morohashi S, et al. (2010) Antiapoptotic effect of the basic helix-loop-helix (bHLH) transcription factor DEC2 in human breast cancer cells. Genes Cells 15: 315-325.
22. Li Y, Shen Q, Kim HT, Bissonnette RP, Lamph WW, et al. (2011) The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor. Breast Cancer Res Treat 128: 667-677.
23. Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, et al. (2012) SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 487: 380-384.
24. Wu Y, Sato F, Bhawal UK, Kawamoto T, Fujimoto K, et al. (2012) BHLH transcription factor DEC2 regulates pro-apoptotic factor Bim in human oral cancer HSC-3 cells. Biomed Res 33: 75-82.
25. Sato F, Bhawal UK, Kawamoto T, Fujimoto K, Imaizumi T, et al. (2008) Basic-helix-loop-helix (bHLH) transcription factor DEC2 negatively regulates vascular endothelial growth factor expression. Genes Cells 13: 131-144. (Pubitemid 351188984)
26. Creasman W (2009) Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 105: 109.
27. Xu Q, Ma P, Hu C, Chen L, Xue L, et al. (2012) Overexpression of the DEC1 protein induces senescence in vitro and is related to better survival in esophageal squamous cell carcinoma. PLoS One 7: e41862.
28. Seeber LM, Horree N, van der Groep P, van der Wall E, Verheijen RH, et al. (2010) Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma. BMC Cancer 10: 307.
29. Shi ZM, Wang J, Yan Z, You YP, Li CY, et al. (2012) MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1. PLoS One 7: e32709.
30. Yang T, Qiu H, Bao W, Li B, Lu C, et al. (2013) Epigenetic inactivation of EFEMP1 is associated with tumor suppressive function in endometrial carcinoma. PLoS One 8: e67458.
31. Jiang F, Liu T, He Y, Yan Q, Chen X, et al. (2011) MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. BMC Cancer 11: 425.
32. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676. (Pubitemid 36749215)
33. Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677-684. (Pubitemid 36749216)
34. Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, et al. (2001) Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 80: 181-188. (Pubitemid 32158456)
35. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, et al. (2007) Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13: 7487-7495.
36. Yokoyama Y, Sato S, Futagami M, Fukushi Y, Sakamoto T, et al. (2000) Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol 77: 413-418. (Pubitemid 30368560)
37. Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK (2007) Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 27: 3525-3528. (Pubitemid 47607497)
38. Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, et al. (2011) Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 29: 2259-2265.
39. Nordgren IK, Tavassoli A (2011) Targeting tumour angiogenesis with small molecule inhibitors of hypoxia inducible factor. Chem Soc Rev 40: 4307-4317.
40. Chen MC, Lee CF, Huang WH, Chou TC (2013) Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1alpha/VEGF signaling pathway in human bladder cancer cells. Biochem Pharmacol 85: 1278-1287.
41. Bhawal UK, Sato F, Arakawa Y, Fujimoto K, Kawamoto T, et al. (2011) Basic helix-loop-helix transcription factor DEC1 negatively regulates cyclin D1. J Pathol 224: 420-429.
42. Gulbagci NT, Li L, Ling B, Gopinadhan S, Walsh M, et al. (2009) SHARP1/DEC2 inhibits adipogenic differentiation by regulating the activity of C/EBP. EMBO Rep 10: 79-86.
43. Rossner MJ, Oster H, Wichert SP, Reinecke L, Wehr MC, et al. (2008) Disturbed clockwork resetting in Sharp-1 and Sharp-2 single and double mutant mice. PLoS One 3: e2762.
44. Hamaguchi H, Fujimoto K, Kawamoto T, Noshiro M, Maemura K, et al. (2004) Expression of the gene for Dec2, a basic helix-loop-helix transcription factor, is regulated by a molecular clock system. Biochem J 382: 43-50. (Pubitemid 39141564)
45. Miyazaki K, Kawamoto T, Tanimoto K, Nishiyama M, Honda H, et al. (2002) Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes. J Biol Chem 277: 47014-47021. (Pubitemid 36159208)
46. Yunokawa M, Tanimoto K, Nakamura H, Nagai N, Kudo Y, et al. (2007) Differential regulation of DEC2 among hypoxia-inducible genes in endometrial carcinomas. Oncol Rep 17: 871-878.
47. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47.
48. Poon E, Harris AL, Ashcroft M (2009) Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med 11: e26.
49. Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127: 679-695. (Pubitemid 44781029)
50. Lu X, Kang Y (2010) Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 16: 5928-5935.